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FGFR3 and PIK3CA mutations in stucco 
keratosis and dermatosis papulosa nigra
Stucco keratosis (STK) and dermatosis papulosa nigra (DPN) 
are benign skin tumours, but their genetic background and 
pathogenesis are not known. The authors describe the pres-
ence of FGFR3 mutations in two cases of DPN and PIK3CA 
mutations in three of five cases of STK. Control tissues 
available for three samples did not show PIK3CA or FGFR3 
mutations. These findings support the concept of these 
lesions as subtypes of seborrhoeic keratosis. Br J Dermatol 
2010; 162:507–11.
Molecular diagnostics of psoriasis, atopic 
dermatitis, allergic contact dermatitis and 
irritant contact dermatitis
Kamsteeg et al. investigated whether atopic dermatitis 
(AD)-associated epidermal gene expression was specif-
ic for AD or could be demonstrated in other eczematous 
conditions such as allergic contact dermatitis (ACD) and 
irritant contact dermatitis (ICD). Normal epidermis and 
psoriatic epidermis were analysed for comparison. Results 
indicated that psoriasis is molecularly quite distinct from 
AD, ACD and ICD and the eczematous conditions showed 
similar expression patterns for some but not for all genes. 
The authors conclude that, using a set of seven genes (CAII, 
NELL2, hBD-2, IL-1F9, CXCL8, CXCL10 and CCL17), a 
molecular distinction can be made between the epider-
mis from normal skin, psoriasis, AD, ACD and ICD. Br J 
Dermatol  2010; 162: 567–77.
The 5-D itch scale: a new measure of pruritus
The 5-D itch questionnaire was developed as a brief but 
multidimensional questionnaire designed to be useful as 
an outcome measure in clinical trials. The five dimen-
sions are duration, degree, direction, disability and 
distribution. Two hundred and thirty-four patients with 
pruritus secondary to primary dermatological disease, 
burn wounds, human immunodeficiency virus, hepato-
bilary  disease or chronic kidney disease completed the 
questionnaire at baseline and at 6-week follow-up. The 
validity of the 5-D instrument was demonstrated by sig-
nificant correlation (P < 0.0001) with a traditional visu-
al analogue scale. Test-retest reliability was confirmed 
with no change in mean 5-D score between day 1 and 
day 3 in untreated individuals (P < 0.0001). Changes in 
pruritus over the 6-week follow-up period were detected 
by the questionnaire (P < 0.0001). The 5-D itch scale is 
reported as a reliable measure of itching in patients with 
chronic pruritus and is able to detect changes over time. 
Br J Dermatol 2010; 162: 586–92.
Topical photodynamic therapy is 
immunosuppressive in humans
This study investigated the in vivo immune effects of 
photo dynamic therapy (PDT) in healthy, Mantoux-
positive volunteers. The Mantoux reaction, a delayed-type 
hypersensitivity, is an accepted model of skin immunity 
in ultraviolet immunosuppression studies in humans. 
Eighteen healthy volunteers were treated with narrowband 
red light with and without prior application of amino-
laevulinic acid (ALA) or methyl aminolaevulinate (MAL) 
with untreated intact control sites. Three days after PDT, 
Mantoux reactions were elicited at each of the sites. Both 
MAL-PDT and ALA-PDT significantly suppressed Mantoux 
erythema (by 30% and 50%, respectively) and diameter 
(41% and 38%). Red light alone significantly suppressed 
diameter (22%) but not erythema (13%). MAL and ALA 
were not immunosuppressive in the absence of irradiation. 
There was no systemic immunosuppression. It is suggested 
that immunosuppression caused by PDT may be an impor-
tant contributor to treatment failures. Br J Dermatol 2010; 
162: 636–40.
Prednisolone vs. ciclosporin for severe adult 
eczema. An investigator-initiated double-
blind placebo-controlled multicentre trial
Schmitt et al. performed a randomized controlled trial 
comparing the efficacy of prednisolone (0.5–0.8 mg kg –1 
daily reduced to nil over 2 weeks) vs. ciclosporin (2.7–4.0 
mg kg –1 daily for 6 weeks) in the treatment of severe 
adult eczema. The primary measure of efficacy was the 
proportion of patients with stable remission at 12 weeks 
follow-up. A sample size of 66 was calculated for clini-
cally relevant differences between the groups. The trial 
was terminated early by an independent safety board as 15 
patients were withdrawn due to disease flare. Thirty-eight 
patients were randomized and analysed. Stable remission 
was achieved in one of 21 patients receiving prednisolone 
compared with six of 17 patients treated with ciclosporin 
(P = 0.031). The study concludes that prednisolone should 
not be recommended to induce stable remission of eczema. 
Br J Dermatol 2010; 162: 660–7.
